Go Pro
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free ALXO Stock Alerts

ALX Oncology (ALXO) Financials

ALX Oncology logo
$2.33 -0.03 (-1.27%)
Closing price 07/8/2026 04:00 PM Eastern
Extended Trading
$2.32 -0.01 (-0.43%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for ALX Oncology

Annual Income Statements for ALX Oncology

This table shows ALX Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -23 -51 0.00 0.00 -161 -135 -102
Consolidated Net Income / (Loss)		 -14 -19 -46 -83 -123 -161 -135 -102
Net Income / (Loss) Continuing Operations		 -14 -19 -46 -83 -123 -161 -135 -102
Total Pre-Tax Income 		-14 -19 -45 -83 -123 -161 -135 -102
Total Operating Income		 -14 -19 -44 -84 -127 -170 -142 -104
Total Gross Profit		 2.07 4.80 1.18 0.00 0.00 0.00 0.00 0.00
Total Revenue		 2.07 4.80 1.18 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 16 24 45 84 127 170 142 104
Selling, General & Admin Expense		 2.60 3.31 15 23 29 28 26 24
Research & Development Expense		 11 16 29 60 98 142 116 77
Impairment Charge		 - - - - - 0.00 0.00 3.18
Total Other Income / (Expense), net		 -0.00 -0.03 -1.84 0.07 4.02 9.47 7.62 2.33
Interest Expense		 0.00 0.00 0.62 0.01 0.24 1.57 1.73 1.60
Interest & Investment Income		 0.00 -0.02 0.12 0.09 4.28 11 9.37 3.96
Other Income / (Expense), net		 -0.00 -0.01 -1.34 -0.01 -0.02 0.39 -0.02 -0.04
Income Tax Expense		 0.05 0.03 0.24 -0.02 0.06 0.00 0.00 0.00
Basic Earnings per Share		 ($6.33) ($7.56) - ($2.07) ($3.03) ($3.74) ($2.58) ($1.90)
Weighted Average Basic Shares Outstanding		 2.75M 3.08M 18.49M 40.31M 40.70M 42.99M 52.17M 53.66M
Diluted Earnings per Share		 ($6.33) ($7.56) - ($2.07) ($3.03) ($3.74) ($2.58) ($1.90)
Weighted Average Diluted Shares Outstanding		 2.75M 3.08M 18.49M 40.31M 40.70M 42.99M 52.17M 53.66M
Weighted Average Basic & Diluted Shares Outstanding		 2.75M 3.08M 18.49M 40.31M 40.86M 50.15M 53.38M 131.61M

Quarterly Income Statements for ALX Oncology

This table shows ALX Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -51 -45 -36 -39 -31 106 -31 -26 -22 -23 -18
Consolidated Net Income / (Loss)		 -51 -45 -36 -39 -31 -29 -31 -26 -22 -23 -18
Net Income / (Loss) Continuing Operations		 -51 -45 -36 -39 -31 -29 -31 -26 -22 -23 -18
Total Pre-Tax Income 		-51 -45 -36 -39 -31 -29 -31 -26 -22 -23 -18
Total Operating Income		 -53 -48 -38 -42 -33 -31 -32 -27 -23 -23 -19
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 53 48 38 42 33 31 32 27 23 23 19
Selling, General & Admin Expense		 7.51 6.24 6.05 6.87 6.10 7.08 7.93 5.45 5.09 5.38 5.36
Research & Development Expense		 46 42 32 35 26 24 24 18 17 18 14
Total Other Income / (Expense), net		 2.29 2.55 2.18 2.13 1.86 1.45 1.07 0.70 0.39 0.17 1.04
Interest Expense		 0.39 0.42 0.43 0.43 0.45 0.43 0.41 0.41 0.41 0.38 0.33
Interest & Investment Income		 2.68 3.00 2.62 2.56 2.30 1.88 1.48 1.11 0.80 0.57 1.18
Other Income / (Expense), net		 -0.00 -0.03 -0.01 -0.01 0.00 -0.00 -0.01 -0.00 -0.01 -0.02 0.19
Basic Earnings per Share		 ($1.24) ($0.92) ($0.71) ($0.76) ($0.58) ($0.53) ($0.58) ($0.49) ($0.41) ($0.42) ($0.17)
Weighted Average Basic Shares Outstanding		 41.15M 42.99M 50.12M 51.83M 52.69M 52.17M 53.36M 53.45M 53.58M 53.66M 104.57M
Diluted Earnings per Share		 ($1.24) ($0.92) ($0.71) ($0.76) ($0.58) ($0.53) ($0.58) ($0.49) ($0.41) ($0.42) ($0.17)
Weighted Average Diluted Shares Outstanding		 41.15M 42.99M 50.12M 51.83M 52.69M 52.17M 53.36M 53.45M 53.58M 53.66M 104.57M
Weighted Average Basic & Diluted Shares Outstanding		 49.82M 50.15M 52.10M 52.67M 52.74M 53.38M 53.44M 53.55M 54.22M 131.61M 134.56M

Annual Cash Flow Statements for ALX Oncology

This table details how cash moves in and out of ALX Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -14 0.76 425 -71 -315 -26 -4.84 -1.19
Net Cash From Operating Activities		 -13 -14 -38 -68 -89 -130 -122 -84
Net Cash From Continuing Operating Activities		 -13 -14 -38 -68 -89 -130 -122 -84
Net Income / (Loss) Continuing Operations		 -14 -19 -46 -83 -123 -161 -135 -102
Consolidated Net Income / (Loss)		 -14 -19 -46 -83 -123 -161 -135 -102
Depreciation Expense		 0.43 0.43 0.20 0.05 0.34 0.84 0.87 0.71
Amortization Expense		 0.00 0.01 0.42 0.00 -0.90 -6.24 -4.39 -0.96
Non-Cash Adjustments To Reconcile Net Income		 0.27 0.30 6.58 19 25 28 29 17
Changes in Operating Assets and Liabilities, net		 -0.16 4.25 0.25 -4.03 9.85 8.30 -12 0.34
Net Cash From Investing Activities		 -0.65 -0.35 0.61 -4.92 -235 45 86 83
Net Cash From Continuing Investing Activities		 -0.65 -0.35 0.61 -4.92 -235 45 86 83
Purchase of Property, Plant & Equipment		 -0.65 -0.35 -0.03 -0.67 -1.43 -1.27 -0.45 -0.21
Purchase of Investments		 - - 0.00 0.00 -377 -247 -107 -52
Sale and/or Maturity of Investments		 - - 0.00 0.00 143 293 194 134
Net Cash From Financing Activities		 0.00 15 463 2.47 9.86 59 31 0.36
Net Cash From Continuing Financing Activities		 0.00 15 463 2.47 9.86 59 31 0.36
Repayment of Debt		 0.00 0.00 -6.51 0.00 -0.66 0.00 0.00 -0.44
Issuance of Common Equity		 0.00 0.00 368 0.20 0.34 59 30 1.71
Other Financing Activities, net		 0.01 0.01 0.30 2.27 0.18 -0.12 0.81 -0.92
Cash Interest Paid		 0.00 0.00 0.43 0.01 0.10 1.18 1.39 1.26
Cash Income Taxes Paid		 0.00 0.00 0.05 0.27 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for ALX Oncology

This table details how cash moves in and out of ALX Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -18 2.82 -8.37 1.49 0.57 1.47 3.05 -1.31 4.14 -7.07 16
Net Cash From Operating Activities		 -31 -40 -38 -27 -25 -32 -25 -23 -17 -19 -19
Net Cash From Continuing Operating Activities		 -31 -40 -38 -27 -25 -32 -25 -23 -17 -19 -19
Net Income / (Loss) Continuing Operations		 -51 -45 -36 -39 -31 -29 -31 -26 -22 -23 -18
Consolidated Net Income / (Loss)		 -51 -45 -36 -39 -31 -29 -31 -26 -22 -23 -18
Depreciation Expense		 0.21 0.21 0.21 0.22 0.22 0.21 0.21 0.19 0.15 0.15 0.15
Amortization Expense		 -1.78 -1.82 -1.49 -1.25 -0.98 -0.67 -0.46 -0.24 -0.15 -0.11 -0.13
Non-Cash Adjustments To Reconcile Net Income		 7.27 7.07 7.49 7.65 7.41 6.33 5.69 5.77 2.92 3.09 2.90
Changes in Operating Assets and Liabilities, net		 14 0.33 -8.56 6.21 -1.32 -8.76 0.65 -3.17 2.12 0.74 -3.64
Net Cash From Investing Activities		 13 -17 26 0.91 26 33 28 22 21 11 -105
Net Cash From Continuing Investing Activities		 13 -17 26 0.91 26 33 28 22 21 11 -105
Purchase of Property, Plant & Equipment		 1.30 -0.15 -0.15 -0.09 -0.15 -0.06 -0.06 -0.05 -0.06 -0.05 -0.05
Purchase of Investments		 -53 -75 -31 -63 -8.71 -4.44 -16 -25 -4.44 -5.97 -124
Sale and/or Maturity of Investments		 64 58 58 64 35 38 43 48 26 17 20
Net Cash From Financing Activities		 -0.11 59 3.09 27 0.25 0.33 0.07 -0.22 -0.16 0.68 140
Net Cash From Continuing Financing Activities		 -0.11 59 3.09 27 0.25 0.33 0.07 -0.22 -0.16 0.68 140
Repayment of Debt		 - - - - - - 0.00 - - - -1.31
Issuance of Common Equity		 - 59 3.02 27 0.08 0.40 0.37 0.02 - 1.33 150
Other Financing Activities, net		 -0.11 0.09 0.06 0.64 0.18 -0.08 -0.31 -0.24 -0.16 -0.21 -9.11

Annual Balance Sheets for ALX Oncology

This table presents ALX Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 11 436 380 306 243 148 59
Total Current Assets		 9.81 436 367 271 189 134 51
Cash & Equivalents		 9.02 434 364 49 22 18 16
Short-Term Investments		 - - 0.00 217 160 110 28
Prepaid Expenses		 0.26 1.77 3.35 4.76 5.92 6.60 5.94
Plant, Property, & Equipment, net		 0.86 0.05 0.90 3.89 3.59 2.91 1.20
Total Noncurrent Assets		 0.01 0.01 12 32 50 11 7.12
Long-Term Investments		 - - 0.00 17 35 3.52 3.49
Other Noncurrent Operating Assets		 0.01 0.01 12 15 15 6.99 3.63
Total Liabilities & Shareholders' Equity		 11 436 380 306 243 148 59
Total Liabilities		 11 6.21 17 43 53 34 33
Total Current Liabilities		 4.98 6.20 15 28 36 19 25
Short-Term Debt		 - - - - 0.00 0.44 5.22
Accounts Payable		 3.75 0.00 5.39 8.07 8.59 4.50 4.91
Accrued Expenses		 1.24 6.13 9.90 19 27 13 14
Other Current Liabilities		 - 0.07 - 1.65 0.54 0.15 0.00
Total Noncurrent Liabilities		 5.97 0.01 1.84 15 17 16 8.51
Long-Term Debt		 5.42 - 0.00 9.39 9.64 9.47 4.53
Other Noncurrent Operating Liabilities		 0.55 0.01 1.84 5.31 7.20 6.19 3.98
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -71 430 363 263 190 114 26
Total Preferred & Common Equity		 -71 430 363 263 190 114 26
Total Common Equity		 -71 430 363 263 190 114 26
Common Stock		 2.14 548 565 590 676 734 749
Retained Earnings		 -73 -119 -202 -325 -486 -621 -723
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.85 0.26 0.28 0.03

Quarterly Balance Sheets for ALX Oncology

This table presents ALX Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 220 213 215 186 121 95 83 178
Total Current Assets		 199 168 169 156 103 85 67 146
Cash & Equivalents		 20 14 16 16 21 19 23 32
Short-Term Investments		 170 143 141 132 77 60 37 108
Prepaid Expenses		 9.06 10 12 7.32 4.70 5.94 5.89 5.24
Plant, Property, & Equipment, net		 3.62 3.44 3.32 3.11 2.70 1.50 1.35 1.05
Total Noncurrent Assets		 17 41 43 27 16 8.57 15 32
Long-Term Investments		 6.44 27 29 14 9.16 4.23 5.84 29
Other Noncurrent Operating Assets		 11 14 13 13 6.50 4.33 9.02 2.93
Total Liabilities & Shareholders' Equity		 220 213 215 186 121 95 83 178
Total Liabilities		 51 48 55 49 33 31 38 27
Total Current Liabilities		 35 32 38 32 19 19 28 20
Short-Term Debt		 - - - - 1.74 3.04 4.35 5.22
Accounts Payable		 13 6.23 8.15 7.89 3.94 4.90 6.58 3.85
Accrued Expenses		 22 26 30 24 13 11 17 11
Other Current Liabilities		 0.27 0.38 0.23 0.06 0.05 0.04 0.00 0.00
Total Noncurrent Liabilities		 16 16 17 17 14 12 10 6.80
Long-Term Debt		 9.58 9.70 9.77 9.84 8.23 7.00 5.76 3.30
Other Noncurrent Operating Liabilities		 6.64 6.52 7.08 6.73 5.63 5.06 4.44 3.51
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 169 164 159 137 88 64 45 151
Total Preferred & Common Equity		 169 164 159 137 88 64 45 151
Total Common Equity		 169 164 159 137 88 64 45 151
Common Stock		 610 686 721 728 740 742 745 892
Retained Earnings		 -441 -522 -561 -592 -652 -678 -700 -741
Accumulated Other Comprehensive Income / (Loss)		 -0.23 0.03 -0.07 0.56 0.12 0.04 0.04 -0.25

Annual Metrics And Ratios for ALX Oncology

This table displays calculated financial ratios and metrics derived from ALX Oncology's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 37,107,522.00 40,499,538.00 40,755,452.00 49,818,812.00 - 54,218,001.00
DEI Adjusted Shares Outstanding		 0.00 0.00 37,107,522.00 40,499,538.00 40,755,452.00 49,818,812.00 - 54,218,001.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.37 0.00 0.00 -3.23 - -1.88
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 132.03% -75.35% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -41.44% -136.71% -88.18% -53.29% -36.93% 16.71% 28.56%
EBIT Growth		 0.00% -40.20% -134.53% -85.69% -52.53% -33.29% 16.13% 26.97%
NOPAT Growth		 0.00% -40.19% -127.61% -91.36% -52.52% -33.62% 16.33% 26.99%
Net Income Growth		 0.00% -40.14% -137.70% -82.47% -47.95% -30.23% 16.14% 24.59%
EPS Growth		 0.00% -19.43% 0.00% 0.00% -46.38% -23.43% 31.02% 26.36%
Operating Cash Flow Growth		 0.00% -8.03% -168.71% -77.86% -31.02% -46.11% 6.48% 30.98%
Free Cash Flow Firm Growth		 0.00% 0.00% -214.59% -107.05% -28.16% -38.46% -0.28% 38.59%
Invested Capital Growth		 0.00% 0.00% -12.96% 85.87% -1,526.70% -86.97% 58.72% -61.80%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -13.24% -3.50% -10.67% 11.30% 7.18%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -13.15% -3.03% -10.28% 10.90% 6.79%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -14.60% -3.03% -10.23% 10.89% 6.80%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -13.10% -1.87% -10.11% 10.79% 5.85%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -1.34% -4.76% 13.13% 5.47%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -38.99% -6.03% -3.70% -17.07% 5.89% 13.44%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.78% -14.84% 2.89% 17.60%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -2,786.96% -63.12% -3.75% 51.41% -8.67%
Profitability Metrics		 - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -641.27% -390.91% -3,754.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -662.02% -399.98% -3,693.99% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -662.12% -400.08% -3,807.28% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -664.30% -401.23% -3,869.71% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.33% 100.18% 100.53% 99.97% 100.05% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.11% 101.10% 99.91% 96.83% 94.65% 94.64% 97.73%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 6,972.10% -21.30% -21.05% -39.42% -70.97% -88.91% -145.70%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -179.73% -20.15% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -180.25% -20.48% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 1,784,428.53% -17.81% -21.05% -39.42% -70.97% -88.91% -145.70%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 27.24% -10.64% -22.99% -46.87% 0.00% -118.69% 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.58 -13 -31 -58 -89 -119 -100 -73
NOPAT Margin		 -463.42% -279.99% -2,585.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -323.41% -6.93% -6.26% -10.76% -17.26% -21.29% -36.12%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -32.69% -59.79% -80.74% -203.79%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 125.83% 69.08% 1,252.88% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 545.23% 339.99% 2,450.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 762.02% 499.98% 3,793.99% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -14 -19 -45 -84 -127 -170 -142 -104
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -19 -44 -84 -128 -175 -146 -104
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 7.44 2.40 1.74 3.91 0.78 2.36
Price to Tangible Book Value (P/TBV)		 0.00 0.00 7.44 2.40 1.74 3.91 0.78 2.36
Price to Revenue (P/Rev)		 73.54 31.69 2,706.15 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 45.61 2,338.79 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 -19.64 0.00 0.00 0.04 0.05 0.09 0.38
Long-Term Debt to Equity		 0.00 -19.64 0.00 0.00 0.04 0.05 0.08 0.17
Financial Leverage		 0.00 13.03 -1.02 -1.01 -1.02 -1.06 -1.09 -1.15
Leverage Ratio		 0.00 -38.68 1.04 1.03 1.10 1.21 1.29 1.48
Compound Leverage Factor		 0.00 -38.72 1.05 1.03 1.06 1.15 1.22 1.45
Debt to Total Capital		 0.00% 105.36% 0.00% 0.00% 3.44% 4.84% 8.02% 27.29%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.35% 14.60%
Long-Term Debt to Total Capital		 0.00% 105.36% 0.00% 0.00% 3.44% 4.84% 7.67% 12.68%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 1,367.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -1,372.96% 100.00% 100.00% 96.56% 95.16% 91.98% 72.71%
Debt to EBITDA		 0.00 -0.29 0.00 0.00 -0.07 -0.06 -0.07 -0.09
Net Debt to EBITDA		 0.00 0.19 0.00 0.00 2.14 1.19 0.83 0.37
Long-Term Debt to EBITDA		 0.00 -0.29 0.00 0.00 -0.07 -0.06 -0.06 -0.04
Debt to NOPAT		 0.00 -0.40 0.00 0.00 -0.11 -0.08 -0.10 -0.13
Net Debt to NOPAT		 0.00 0.27 0.00 0.00 3.07 1.75 1.22 0.53
Long-Term Debt to NOPAT		 0.00 -0.40 0.00 0.00 -0.11 -0.08 -0.09 -0.06
Altman Z-Score		 0.00 -6.16 309.56 30.12 4.50 4.06 -6.58 -21.31
Noncontrolling Interest Sharing Ratio		 0.00% -25,493.84% 16.38% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 1.97 70.28 24.00 9.57 5.24 7.26 2.07
Quick Ratio		 0.00 1.92 69.99 23.78 9.40 5.08 6.91 1.82
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -9.56 -30 -62 -80 -110 -111 -68
Operating Cash Flow to CapEx		 -2,019.91% -4,036.54% 0.00% -10,225.38% -6,252.49% -10,232.65% -27,273.38% -39,689.62%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -48.41 -4,788.04 -335.17 -70.58 -64.06 -42.46
Operating Cash Flow to Interest Expense		 0.00 0.00 -61.66 -5,238.54 -374.89 -83.30 -70.51 -52.52
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -60.67 -5,289.77 -380.88 -84.11 -70.77 -52.66
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.45 0.01 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 8.95 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 5.58 2.59 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 40.79 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 40.79 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 -3.87 -4.37 -0.62 -10 -19 -7.76 -13
Invested Capital Turnover		 0.00 -2.48 -0.29 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -3.87 -0.50 3.76 -9.44 -8.74 11 -4.80
Enterprise Value (EV)		 0.00 219 2,764 507 186 533 -33 23
Market Capitalization		 152 152 3,199 870 459 742 88 61
Book Value per Share		 $0.00 ($22.96) $11.58 $8.96 $6.46 $3.81 $2.15 $0.48
Tangible Book Value per Share		 $0.00 ($22.96) $11.58 $8.96 $6.46 $3.81 $2.15 $0.48
Total Capital		 0.00 5.15 430 363 273 199 124 36
Total Debt		 0.00 5.42 0.00 0.00 9.39 9.64 9.90 9.75
Total Long-Term Debt		 0.00 5.42 0.00 0.00 9.39 9.64 9.47 4.53
Net Debt		 0.00 -3.60 -434 -364 -274 -209 -121 -39
Capital Expenditures (CapEx)		 0.65 0.35 -0.61 0.67 1.43 1.27 0.45 0.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -4.19 -4.43 -12 -24 -30 -11 -13
Debt-free Net Working Capital (DFNWC)		 0.00 4.83 430 352 243 153 116 31
Net Working Capital (NWC)		 0.00 4.83 430 352 243 153 116 26
Net Nonoperating Expense (NNE)		 4.15 5.81 15 25 34 42 35 29
Net Nonoperating Obligations (NNO)		 0.00 -3.60 -434 -364 -274 -209 -121 -39
Total Depreciation and Amortization (D&A)		 0.43 0.44 0.62 0.05 -0.55 -5.40 -3.52 -0.26
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -87.41% -374.87% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 100.60% 36,361.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 100.60% 36,361.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($2.07) $0.00 ($3.74) ($2.58) ($1.90)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 40.13M 40.63M 40.70M 42.99M 52.17M 53.66M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.07) $0.00 ($3.74) ($2.58) ($1.90)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 40.13M 40.63M 40.70M 42.99M 52.17M 53.66M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.07) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 18.49M 40.31M 40.86M 50.15M 53.38M 131.61M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.58 -13 -31 -58 -89 -119 -100 -71
Normalized NOPAT Margin		 -463.42% -279.99% -2,585.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -662.12% -400.52% -3,849.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -72.47 -6,427.85 -535.54 -108.56 -82.41 -64.95
NOPAT to Interest Expense		 0.00 0.00 -49.22 -4,499.12 -374.81 -76.16 -57.68 -45.45
EBIT Less CapEx to Interest Expense		 0.00 0.00 -71.48 -6,479.08 -541.53 -109.37 -82.67 -65.09
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -48.24 -4,550.35 -380.81 -76.98 -57.94 -45.58
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.04% 0.00% -8.41% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for ALX Oncology

This table displays calculated financial ratios and metrics derived from ALX Oncology's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 41,151,819.00 49,818,812.00 50,152,082.00 52,100,107.00 52,671,790.00 - 53,384,145.00 53,444,020.00 53,551,134.00 54,218,001.00 131,608,278.00
DEI Adjusted Shares Outstanding		 41,151,819.00 49,818,812.00 50,152,082.00 52,100,107.00 52,671,790.00 - 53,384,145.00 53,444,020.00 53,551,134.00 54,218,001.00 131,608,278.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.24 -0.91 -0.71 -0.76 -0.58 - -0.58 -0.49 -0.41 -0.42 -0.14
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -48.43% -51.61% -18.52% -12.50% 39.24% 37.44% 17.85% 37.27% 32.39% 25.97% 41.52%
EBIT Growth		 -45.21% -49.13% -17.65% -13.94% 38.88% 36.29% 15.74% 35.83% 30.79% 24.75% 41.01%
NOPAT Growth		 -45.24% -49.05% -17.26% -12.91% 38.87% 36.25% 15.74% 35.83% 30.81% 24.80% 40.40%
Net Income Growth		 -44.37% -48.07% -17.88% -15.34% 39.78% 35.87% 13.57% 34.14% 27.89% 21.65% 41.71%
EPS Growth		 -42.53% -22.67% 4.05% 9.52% 53.23% 42.39% 18.31% 35.53% 29.31% 20.75% 70.69%
Operating Cash Flow Growth		 -0.89% -91.98% -36.34% 16.22% 18.56% 19.23% 34.97% 11.89% 32.64% 40.77% 24.39%
Free Cash Flow Firm Growth		 -30.00% -89.61% -54.77% 54.63% 1.55% -30.53% -8.86% -87.39% 19.07% 65.13% 47.16%
Invested Capital Growth		 -193.96% -86.97% -67.37% -650.86% 11.86% 58.72% 17.59% 46.87% 27.66% -61.80% -5.98%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -44.96% 9.45% 21.37% -9.00% 21.71% 6.77% -3.25% 16.76% 15.61% -2.08% 18.44%
EBIT Q/Q Growth		 -46.15% 9.81% 21.39% -9.95% 21.59% 5.99% -3.98% 16.28% 15.43% -2.22% 18.49%
NOPAT Q/Q Growth		 -44.86% 9.86% 21.37% -9.97% 21.57% 6.00% -3.94% 16.25% 15.45% -2.17% 17.61%
Net Income Q/Q Growth		 -49.27% 10.82% 21.75% -10.73% 22.06% 5.03% -5.46% 15.62% 14.66% -3.18% 21.54%
EPS Q/Q Growth		 -47.62% 25.81% 22.83% -7.04% 23.68% 8.62% -9.43% 15.52% 16.33% -2.44% 59.52%
Operating Cash Flow Q/Q Growth		 1.74% -27.34% 4.42% 29.95% 4.48% -26.28% 23.04% 5.10% 26.97% -11.04% 1.75%
Free Cash Flow Firm Q/Q Growth		 19.23% 1.84% 10.86% 35.80% -75.25% -30.15% 25.66% -10.52% 24.32% 43.93% -12.67%
Invested Capital Q/Q Growth		 -694.95% -3.75% 43.67% -61.62% 6.69% 51.41% -12.46% -4.18% -27.07% -8.67% 26.33%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.71% 94.63% 94.19% 94.86% 94.30% 95.26% 96.62% 97.37% 98.25% 99.18% 95.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -64.09% -70.97% -82.16% -92.17% -98.94% -88.91% -102.99% -104.21% -118.95% -145.70% -74.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -64.09% -70.97% -82.16% -92.17% -98.94% -88.91% -102.99% -104.21% -118.95% -145.70% -74.17%
Return on Equity Simple (ROE_SIMPLE)		 -86.54% 0.00% -101.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -37 -34 -26 -29 -23 -21 -22 -19 -16 -16 -13
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.71% -4.92% -4.34% -5.28% -4.66% -4.69% -6.24% -5.84% -6.09% -8.42% -3.61%
Return On Investment Capital (ROIC_SIMPLE)		 - -16.86% -15.20% -17.19% -15.55% -17.35% -22.67% -25.05% -28.72% -45.10% -8.30%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -53 -48 -38 -42 -33 -31 -32 -27 -23 -23 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -55 -50 -39 -43 -33 -31 -32 -27 -23 -23 -19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.17 3.91 3.41 1.97 0.70 0.78 0.38 0.34 2.19 2.36 1.74
Price to Tangible Book Value (P/TBV)		 1.17 3.91 3.41 1.97 0.70 0.78 0.38 0.34 2.19 2.36 1.74
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 9.94 0.00 0.00 1.21 3.65 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 10.06% 0.00% 0.00% 82.39% 27.39% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.06 0.05 0.06 0.06 0.07 0.09 0.11 0.16 0.23 0.38 0.06
Long-Term Debt to Equity		 0.06 0.05 0.06 0.06 0.07 0.08 0.09 0.11 0.13 0.17 0.02
Financial Leverage		 -1.05 -1.06 -1.04 -1.05 -1.11 -1.09 -1.08 -1.12 -1.15 -1.15 -1.08
Leverage Ratio		 1.18 1.21 1.21 1.24 1.33 1.29 1.32 1.39 1.48 1.48 1.25
Compound Leverage Factor		 1.13 1.15 1.14 1.17 1.25 1.23 1.28 1.35 1.45 1.47 1.19
Debt to Total Capital		 5.37% 4.84% 5.58% 5.78% 6.71% 8.02% 10.15% 13.48% 18.41% 27.29% 5.32%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.35% 1.77% 4.09% 7.92% 14.60% 3.26%
Long-Term Debt to Total Capital		 5.37% 4.84% 5.58% 5.78% 6.71% 7.67% 8.38% 9.40% 10.50% 12.68% 2.06%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 94.63% 95.16% 94.42% 94.22% 93.29% 91.98% 89.85% 86.52% 81.59% 72.71% 94.68%
Debt to EBITDA		 -0.06 -0.06 -0.05 -0.05 -0.06 -0.07 -0.07 -0.08 -0.09 -0.09 -0.09
Net Debt to EBITDA		 1.18 1.19 0.96 0.95 0.93 0.83 0.70 0.60 0.50 0.37 1.76
Long-Term Debt to EBITDA		 -0.06 -0.06 -0.05 -0.05 -0.06 -0.06 -0.06 -0.06 -0.05 -0.04 -0.04
Debt to NOPAT		 -0.09 -0.08 -0.08 -0.08 -0.09 -0.10 -0.10 -0.12 -0.13 -0.13 -0.13
Net Debt to NOPAT		 1.73 1.75 1.42 1.40 1.37 1.22 1.02 0.86 0.72 0.53 2.52
Long-Term Debt to NOPAT		 -0.09 -0.08 -0.08 -0.08 -0.09 -0.09 -0.09 -0.08 -0.07 -0.06 -0.05
Altman Z-Score		 -0.40 5.72 3.67 -0.16 -3.07 -4.08 -6.97 -9.61 -10.63 -16.78 0.55
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.66 5.24 5.21 4.39 4.82 7.26 5.47 4.52 2.40 2.07 7.21
Quick Ratio		 5.41 5.08 4.89 4.08 4.59 6.91 5.22 4.21 2.19 1.82 6.95
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 -25 -22 -14 -25 -32 -24 -27 -20 -11 -13
Operating Cash Flow to CapEx		 0.00% -26,809.46% -25,624.32% -29,517.78% -17,030.87% -53,410.00% -41,105.00% -49,800.00% -30,523.21% -38,734.69% -37,296.00%
Free Cash Flow to Firm to Interest Expense		 -64.80 -59.94 -51.92 -33.18 -55.93 -76.03 -59.45 -65.86 -49.48 -29.56 -38.53
Operating Cash Flow to Interest Expense		 -79.69 -95.61 -88.82 -61.93 -56.90 -75.05 -60.75 -57.79 -41.89 -49.56 -56.34
Operating Cash Flow Less CapEx to Interest Expense		 -76.36 -95.97 -89.16 -62.14 -57.23 -75.19 -60.89 -57.91 -42.03 -49.68 -56.49
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -18 -19 -11 -17 -16 -7.76 -8.73 -9.09 -12 -13 -9.25
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -12 -8.74 -4.26 -15 2.15 11 1.86 8.02 4.42 -4.80 -0.52
Enterprise Value (EV)		 11 533 384 138 -57 -33 -64 -51 42 23 103
Market Capitalization		 198 742 559 314 96 88 33 22 98 61 264
Book Value per Share		 $4.10 $3.81 $3.27 $3.06 $2.60 $2.15 $1.65 $1.21 $0.84 $0.48 $1.15
Tangible Book Value per Share		 $4.10 $3.81 $3.27 $3.06 $2.60 $2.15 $1.65 $1.21 $0.84 $0.48 $1.15
Total Capital		 178 199 174 169 147 124 98 74 55 36 160
Total Debt		 9.58 9.64 9.70 9.77 9.84 9.90 9.97 10 10 9.75 8.51
Total Long-Term Debt		 9.58 9.64 9.70 9.77 9.84 9.47 8.23 7.00 5.76 4.53 3.30
Net Debt		 -187 -209 -175 -176 -153 -121 -97 -74 -56 -39 -161
Capital Expenditures (CapEx)		 -1.30 0.15 0.15 0.09 0.15 0.06 0.06 0.05 0.06 0.05 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -26 -30 -22 -26 -25 -11 -12 -9.86 -17 -13 -9.72
Debt-free Net Working Capital (DFNWC)		 164 153 136 130 124 116 86 69 43 31 131
Net Working Capital (NWC)		 164 153 136 130 124 116 84 66 39 26 125
Net Nonoperating Expense (NNE)		 14 12 9.15 10 7.91 7.73 8.48 7.30 6.37 6.73 4.65
Net Nonoperating Obligations (NNO)		 -187 -209 -175 -176 -153 -121 -97 -74 -56 -39 -161
Total Depreciation and Amortization (D&A)		 -1.57 -1.61 -1.28 -1.03 -0.76 -0.45 -0.25 -0.05 0.01 0.04 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.24) ($0.92) ($0.71) ($0.76) ($0.58) ($0.53) ($0.58) ($0.49) ($0.41) ($0.42) ($0.17)
Adjusted Weighted Average Basic Shares Outstanding		 41.15M 42.99M 50.12M 51.83M 52.69M 52.17M 53.36M 53.45M 53.58M 53.66M 104.57M
Adjusted Diluted Earnings per Share		 ($1.24) ($0.92) ($0.71) ($0.76) ($0.58) ($0.53) ($0.58) ($0.49) ($0.41) ($0.42) ($0.17)
Adjusted Weighted Average Diluted Shares Outstanding		 41.15M 42.99M 50.12M 51.83M 52.69M 52.17M 53.36M 53.45M 53.58M 53.66M 104.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.82M 50.15M 52.10M 52.67M 52.74M 53.38M 53.44M 53.55M 54.22M 131.61M 134.56M
Normalized Net Operating Profit after Tax (NOPAT)		 -37 -34 -26 -29 -23 -21 -22 -16 -16 -16 -13
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -136.26 -115.79 -88.47 -96.81 -73.01 -71.70 -78.40 -65.80 -55.24 -60.15 -56.73
NOPAT to Interest Expense		 -95.38 -81.00 -61.90 -67.76 -51.11 -50.19 -54.86 -46.06 -38.66 -42.07 -40.11
EBIT Less CapEx to Interest Expense		 -132.92 -116.14 -88.82 -97.02 -73.35 -71.84 -78.55 -65.92 -55.38 -60.28 -56.88
NOPAT Less CapEx to Interest Expense		 -92.04 -81.36 -62.25 -67.97 -51.45 -50.33 -55.01 -46.17 -38.80 -42.20 -40.26
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ALX Oncology’s latest quarter shows a company still burning cash, but with a much stronger liquidity position than it had a year ago. The key story for retail investors is that ALXO remains pre-revenue, so losses are expected, but it ended Q1 2026 with a sizable cash and investment cushion after a large common equity raise. That gives it more runway, even though operating performance is still under pressure.

  • Cash and investments improved sharply. ALXO reported $141.1 million in cash, short-term investments, and long-term investments at Q1 2026, up from about $125.3 million at the end of Q3 2025 and $95.0 million at Q2 2025.
  • Liquidity runway appears stronger. The balance sheet showed $145.6 million in current assets versus $20.2 million in current liabilities, a healthy short-term coverage profile for a development-stage biotech company.
  • Equity financing boosted the cash position. Q1 2026 included $150.0 million of common equity issuance, which was the main reason cash increased despite ongoing operating losses.
  • Interest and investment income offset some losses. In Q1 2026, ALXO generated $1.182 million of interest and investment income, helping reduce the pre-tax loss relative to operating loss.
  • Operating cash burn improved year over year. Net cash used in operating activities was $18.6 million in Q1 2026 versus $24.7 million in Q1 2025 and $32.0 million in Q4 2024.
  • Operating expenses were lower than prior quarters. Q1 2026 operating expenses totaled $19.0 million, down from $23.0 million in Q4 2025 and well below the $31.8 million run rate in Q1 2025.
  • ALXO still has no revenue. The company reported $0 in revenue again, so valuation remains entirely dependent on clinical and pipeline progress.
  • Net losses remain large. Q1 2026 net loss was $17.9 million, though that was an improvement from $22.8 million in Q4 2025 and $30.8 million in Q1 2025.
  • Shares outstanding jumped materially. Q1 2026 basic shares were about 104.6 million, up sharply from 53.7 million in Q4 2025, reflecting substantial dilution from the capital raise.
  • Dilution is a major concern. The large equity raise strengthened the balance sheet, but it also significantly diluted existing shareholders.
  • The company is still cash-flow negative. Even after the capital raise, ALXO used $18.6 million in operations during the quarter, so it is not self-funding.
  • Losses have been persistent for years. Recent quarters show a long pattern of operating losses, with quarterly net losses ranging from roughly $17.9 million to more than $50.0 million over the last four years.
  • Balance-sheet strength has been volatile. Total equity fell sharply from $159.3 million in Q2 2024 to $44.8 million in Q3 2025 before rebounding to $151.3 million in Q1 2026, underscoring how dependent the company is on financing and market access.

Bottom line: ALX Oncology looks better capitalized now than it did several quarters ago, which reduces near-term bankruptcy risk. But the business is still pre-revenue, still burning cash, and still reliant on outside funding. For investors, the stock remains a high-risk biotech story where clinical progress will matter far more than current financial results.

07/09/26 06:25 AM ETAI Generated. May Contain Errors.

ALX Oncology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ALX Oncology's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

ALX Oncology's net income appears to be on an upward trend, with a most recent value of -$101.70 million in 2025, rising from -$13.73 million in 2018. The previous period was -$134.85 million in 2024. Check out ALX Oncology's forecast to explore projected trends and price targets.

ALX Oncology's total operating income in 2025 was -$104.02 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $104.02 million

Over the last 7 years, ALX Oncology's total revenue changed from $2.07 million in 2018 to $0.00 in 2025, a change of -100.0%.

ALX Oncology's total liabilities were at $33.07 million at the end of 2025, a 3.2% decrease from 2024, and a 201.9% increase since 2019.

In the past 6 years, ALX Oncology's cash and equivalents has ranged from $9.02 million in 2019 to $434.22 million in 2020, and is currently $16.37 million as of their latest financial filing in 2025.

Over the last 7 years, ALX Oncology's book value per share changed from 0.00 in 2018 to 0.48 in 2025, a change of 47.9%.


Related Companies

Financial statements for NASDAQ:ALXO last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel